Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q3 FY2026 Earnings Presentation
22 slides from Strides Pharma Science's earnings presentation, Jan 30, 2026
Slide 1: Exchange filing cover letter for press release
January 30, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Symbol: STAR Dear Madam/ Sir, Sub: Press Release Please find enclosed herewith Press Rel
Slide 2: Press Release: Highest Ever Quarterly EBITDA in Q3FY26
Press Release January 30, 2026 Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of 2,359m in Q3FY26 82 9% YoY Tepid Revenue Growth at 3.6%, Impacted by Low Offtake in Institutional Business and Flattish US Operations Compensated by Strong Ex-US Business, which
Slide 3: Press release contact details
and an institutional business to service donor- Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company at the Compan www.strides.com. For further information, please contact: Institutional Investors Corporate Communication
Slide 4: Exchange filing cover letter for earnings presentation
January 30, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Symbol: STAR Dear Sirs, Sub: Earnings Presentation for the quarter and nine months ended
Slide 5: Q3FY26 Earnings Presentation
Q3FY26 Earnings Presentation January 30, 2026 Strides Pharma Science Limited 1
Slide 6: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 7: Strides Continues to Deliver Exceptional Performance
Strides Continues to Deliver Exceptional Performance With Highest Tepid Revenue Growth at 3.6%, Impacted by Low Offtake in Institutional Business and Flattish US Operations Compensated by Strong Ex-US Business, which Grew 20% YoY Q3FY26 Q3FY25 YoY Change continues to deliver a strong performance in
Slide 8: Consistent Growth Across Key Metrics in 9MFY26
Strides Delivers Consistent Growth Across Key Metrics in 9MFY26 9MFY26 9MFY25 YoY Change Revenue ( 35,352 33,749 YoY 4.7% Gross Margins ( 21,127 18,939 11.6% Gross Margin (%) 59.8% 56.1% 370bps EBITDA ( 6,856 5,849 17.2% EBITDA Margin (%) 19.4% 17.3% 210bps Operational PAT ( 3,824 2,317 65.0% Operat
Slide 9: Consistent Growth in Absolute Gross Margin, EBITDA and PAT
Consistent Growth in Absolute Gross Margin, EBITDA and PAT $137 $141 $131 $141 $136 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Gross Margin (%) EBITDA Margin (%) Operational EPS Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY
Slide 10: Ex-US Market Registers a Strong Growth of 20% YoY
Ex-US Market Registers a Strong Growth of 20% YoY Ex-US Markets are on track to mirror the US Market over the next two years US Market Ex-US Markets Access Market* 222, 2% YoY 0% YoY 20% YoY 70% 5,620, 6,105, 47% 51% Q3FY25 Q3FY26 Q3FY25 Q3FY26 US Ex-US Access Market Q3FY25 Q3FY26 Growth Markets ORM
Slide 11: US Market
CELEBRATING S strides SE. US Market
Slide 12: Q3FY26 US Revenue at $70m, Steady Despite New Entrants
US Market Q3FY26 Revenue at $70m, Remained Steady Despite New Entrants in Recent Launches Year-on-Year Comparison Comments Q3FY26 revenues at $70m, remained steady despite new entrants in recent launches YoY 0% Launched 4 products in 9MFY26 $73 $70 Discontinued 8 products in 9MFY26 that did not meet
Slide 13: Ex-US Markets
CELEBRATING S strides SE. Ex-US Markets
Slide 14: Ex-US Market Revenue at $64m, Grew 20% YoY
Ex-US Markets Ex-US Market Revenue at $64m, Grew 20% YoY Growth driven by all key markets across Australia, UK and EU Year-on-Year Comparison Comments Other Regulated Markets YoY 20% $56 $64 All regulated markets ex-US form part of the Other Regulated Markets Q3FY26 ORM Revenue at $47.6m, Grew 21% Y
Slide 15: Financial Performance
Financial Performance Strong Financial Discipline Enabled Profitability and Cashflow Generation
Slide 16: Income Statement Reported Strong PAT in Q3FY26
Income Statement Reported Strong PAT in Q3FY26 Particulars Q3FY26 Q3FY25 YoY Q2FY26 QoQ 9MFY26 9MFY25 YoY I. Revenue 11,946 11,537 3.6% 12,208 -2.1% 35,352 33,749 4.7% II. Material Costs 4,629 4,801 5,153 14,225 14,810 III. Gross Margin (I- II) 7,317 6,735 8.6% 7,056 3.7% 21,127 18,939 11.6% Gross M
Slide 17: Net Debt and Net Finance Cost
) Q2FY26 Q3FY26 Working Capital Loans 11,364 9,363 Long Term Loans 6,593 6,055 Interest Cost on Borrowings (A) 370 353 Gross Debt 17,956 15,417 Other Finance Charges (B) 91 81 Cash and Cash Equivalents# (2,734) (1,890) Net Debt at Constant Currency 15,222 13,527 Finance Income (C) 257^ 37 Currency I
Slide 18: Significant Improvement in Balance Sheet Metrics
Strong Oversight and Governance Leading to Significant Improvement in the Balance Sheet Metrics Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 1.0 3.5 129 124 117 0.6 0.5 1.9 1.6 FY24 FY25 Q3FY26 FY24 FY25 Q3FY26 FY24 FY25 Q3FY26 Current Ratio (x) RoCE (%) Fixed Asset Turnov
Slide 19: Corporate Updates
CELEBRATING S strides SE. Corporate Updates
Slide 20: Strengthening Leadership Team
Strengthening Leadership Team Peter Hardwick Nandini Matiyani Chief Executive Officer North America Executive Vice President - Human Resources Peter brings 30+ years of global pharmaceutical leadership spanning Nandini brings over 20 years of experience in people strategy, sales, marketing, portfoli
Slide 21: Q3FY26 Earnings Call Details
Q3FY26 Earnings Call Details invites you to interact with the senior management on Q3FY26 Performance Click here to pre-register and join without the operator Jan 30, 2026 4:30 pm IST / 11:00 am GMT / 7:00 am EDT / 7:00 pm HKT Join through an operator using dial in numbers Participants from the Mana
Slide 22: Strides Pharma Science Limited Corporate and Registered Office
Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corporate Office Strides House, Bannerghatta Road, Bengaluru - 560 076, India Tel.: +91 80 6784 0000/ 6784 0290 Email: Investor-Relations@strides.com Registered Office Vashi, Navi Mumbai - 400 703 Tel.: +91 22 2789 2924/2789 3199 Website: www
Strides Pharma Science — Q3 FY2026 Earnings Presentation on 6ix